Pfizer On Track To Settle Rapamune Investigation; Protonix Probe Still Unresolved
This article was originally published in The Pink Sheet Daily
Pfizer has reached an agreement-in-principle with the Department of Justice in the Rapamune investigation and taken a charge of $491 million; Novartis settles allegations over the marketing of Elidel for $19.9 million.
You may also be interested in...
Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.
Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.
Pfizer reaches separate settlements with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.